Literature DB >> 2872248

Vasoactive intestinal peptide.

S I Said.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 2872248     DOI： 10.1007/BF03348097

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  129 in total

1.  Vasoactive intestinal peptide in the regulation of renin secretion.

Authors:  J P Porter; T N Thrasher; S I Said; W F Ganong
Journal:  Am J Physiol       Date:  1985-07

2.  Vasoactive intestinal polypeptide and muscarinic receptors: supersensitivity induced by long-term atropine treatment.

Authors:  B Hedlund; J Abens; T Bartfai
Journal:  Science       Date:  1983-04-29       Impact factor: 47.728

3.  Vasoactive intestinal peptide stimulates hormone release from corticotropic cells in culture.

Authors:  J M Westendorf; M A Phillips; A Schonbrunn
Journal:  Endocrinology       Date:  1983-02       Impact factor: 4.736

4.  Nerve growth factor increases substance P, cholecystokinin and vasoactive intestinal polypeptide immunoreactivities in primary sensory neurones of newborn rats.

Authors:  U Otten; H P Lorez
Journal:  Neurosci Lett       Date:  1982-12-30       Impact factor: 3.046

5.  Ultrastructural localization of VIP-like immunoreactivity in large dense-core vesicles of 'cholinergic-type' nerve terminals in cat exocrine glands.

Authors:  O Johansson; J M Lundberg
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

6.  Preferential binding of vasoactive intestinal polypeptide to basolateral membrane of rat and rabbit enterocytes.

Authors:  K Dharmsathaphorn; V Harms; D J Yamashiro; R J Hughes; H J Binder; E M Wright
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

7.  Effect of vasoactive intestinal peptide (VIP) and other peptides on cAMP accumulation in rat brain.

Authors:  M Quik; L L Iversen; S R Bloom
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

8.  Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erection.

Authors:  E Willis; B Ottesen; G Wagner; F Sundler; J Fahrenkrug
Journal:  Acta Physiol Scand       Date:  1981-12

9.  Origin of cholinergic nerves to the rat major cerebral arteries: coexistence with vasoactive intestinal polypeptide.

Authors:  H Hara; G S Hamill; D M Jacobowitz
Journal:  Brain Res Bull       Date:  1985-02       Impact factor: 4.077

10.  The origins, pathways and terminations of neurons with VIP-like immunoreactivity in the guinea-pig small intestine.

Authors:  M Costa; J B Furness
Journal:  Neuroscience       Date:  1983-04       Impact factor: 3.590
View more
  24 in total

Review 1.  Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.

Authors:  B M Lodde; B J Baum; P P Tak; G Illei
Journal:  Ann Rheum Dis       Date:  2006-07-31       Impact factor: 19.103

2.  Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome.

Authors:  A Brunani; C Crespi; M De Martin; A Dubini; M Piolini; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1991-09       Impact factor: 4.256

3.  Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS.

Authors:  Bo Gao; Stephan R Vavricka; Peter J Meier; Bruno Stieger
Journal:  Pflugers Arch       Date:  2014-08-19       Impact factor: 3.657

4.  Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.

Authors:  M Xia; S P Sreedharan; E J Goetzl
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

5.  Decreased REM sleep and altered circadian sleep regulation in mice lacking vasoactive intestinal polypeptide.

Authors:  Wang-Ping Hu; Jia-Da Li; Christopher S Colwell; Qun-Yong Zhou
Journal:  Sleep       Date:  2011-01-01       Impact factor: 5.849

6.  Role of vasoactive intestinal polypeptide in the internal anal sphincter relaxation of the opossum.

Authors:  S Nurko; S Rattan
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

Review 7.  VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment.

Authors:  J M Muller; V Lelievre; L Becq-Giraudon; A C Meunier
Journal:  Mol Neurobiol       Date:  1995 Apr-Jun       Impact factor: 5.590

8.  Transfection of fetal rat intestinal epithelial cells by viral oncogenes: establishment and characterization of the E1A-immortalized SLC-11 cell line.

Authors:  S Emami; L Mir; C Gespach; G Rosselin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

9.  Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells.

Authors:  Orhan Tansel Korkmaz; Neşe Tunçel; Muzaffer Tunçel; Elif Mine Oncü; Varol Sahintürk; Mustafa Celik
Journal:  J Mol Neurosci       Date:  2009-12-02       Impact factor: 3.444

10.  Measurement of intracellular mediators in enterocytes isolated from jejunal biopsy specimens of control and cystic fibrosis patients.

Authors:  B W Hitchin; P R Dobson; B L Brown; J Hardcastle; P T Hardcastle; C J Taylor
Journal:  Gut       Date:  1991-08       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.